Full Answer
CYP2D6 is an enzyme that is responsible for breaking down (metabolizing) many of the drugs that are commonly used today. Some medications, such as codeine, require activation by CYP2D6 in order for the medication to be effective.
Some medications, such as codeine, require activation by CYP2D6 in order for the medication to be effective. Other drugs, such as tricyclic antidepressants (e.g., amitriptyline and imipramine), are metabolized to forms that are not active and are more easily eliminated from the body.
Deficiency, deficient. methylenetetrahydrofolate reductase E72.12 (MTHFR) Disorder (of) - see also Disease. metabolism NOS E88.9. ICD-10-CM Diagnosis Code E88.9. Metabolic disorder, unspecified. 2016 2017 2018 2019 2020 2021 Billable/Specific Code. amino-acid E72.9. ICD-10-CM Diagnosis Code E72.9.
Methylenetetrahydrofolate reductase mutation. ICD-10-CM E72.12 is grouped within Diagnostic Related Group (s) (MS-DRG v38.0): 642 Inborn and other disorders of metabolism. Convert E72.12 to ICD-9-CM.
CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
This First Coast Billing and Coding Article for Local Coverage Determination (LCD) L35698 CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing provides billing and coding guidance for frequency limitations as well as diagnosis limitations that support diagnosis to procedure code automated denials.
It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim (s) submitted.
All those not listed under the “ICD-10 Codes that Support Medical Necessity” section of this article.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.
CYP2D6 is an enzyme that is responsible for breaking down (metabolizing) many of the drugs that are commonly used today. Some medications, such as codeine, require activation by CYP2D6 in order for the medication to be effective.
We do not routinely adjust medicine doses based on the following genotypes, except in rare instances: Intermediate metabolizers – These subjects metabolize drugs at a rate somewhere between the poor and normal metabolizers. About 1 in 10 people are intermediate metabolizers. Drugs we recommend to adjust the dose:
Fluoxetine. Blood levels of fluoxetine and its active metabolite are likely to be low; therefore these patients may not respond well to this medicine. Paroxetine. Blood levels of paroxetine are likely to be low; therefore these patients may not respond well to this medicine.
Ondansetron may not be as effective for management of nausea and vomiting in these patients. Other antiemetics not metabolized by CYP2D6 (such as granisetron) are recommended. Other drugs may be affected. The PG4KDS study will evaluate what should be done for the dosing of these other drugs.
Codeine has no analgesic effect in these patients. Other pain medications such as a non-opioid agent, morphine, HYDROmorphone (e.g.: Dilaudid®), oxyCODONE or acetaminophen/hydroCODONE (e.g.: Lortab®, Vicodin®) are recommended. Tramadol.